Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044796 | 0.84 | TDP1 (0.50) | MAPTALDH1A1GAAMAPK1L3MBTL1 | |
| SCHEMBL56425 | 0.80 | CA1 (0.50) | ALDH1A1POLBMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3191755 | 0.80 | MAPT (0.69) | MAPTALDH1A1NPC1RAB9AGAA | |
| SCHEMBL8459532 | 0.78 | CA1 (0.48) | ALDH1A1POLBMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5923798 | 0.78 | MAPT (0.67) | MAPTALDH1A1NPC1RAB9AGAA | |
| SCHEMBL13800740 | 0.77 | SLC2A1 (0.41) | MAPTALDH1A1NPC1RAB9APOLB | |
| SCHEMBL4124328 | 0.77 | MAPT (0.49) | MAPTALDH1A1NPC1RAB9AGAA | |
| SCHEMBL30992110 | 0.76 | CA1 (0.50) | ALDH1A1POLBMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL476857 | 0.76 | CA1 (0.50) | ALDH1A1POLBMAPK1L3MBTL1SMN1; SMN2 | |
| SCHEMBL16318152 | 0.75 | CYP3A4 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-20090163740-A1 | LIGANDS FOR METALS AS CATALYSTS FOR CARBON-CARBON BOND FORMATION | NATIONAL SUN YAT-SEN UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163740-A1 | LIGANDS FOR METALS AS CATALYSTS FOR CARBON-CARBON BOND FORMATION | NATIONAL SUN YAT-SEN UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163740-A1 | LIGANDS FOR METALS AS CATALYSTS FOR CARBON-CARBON BOND FORMATION | NATIONAL SUN YAT-SEN UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163740-A1 | LIGANDS FOR METALS AS CATALYSTS FOR CARBON-CARBON BOND FORMATION | NCOR2, OXGR1, NCOR1 | MAPT 3482/4885ALDH1A1 2127/4885NPC1 1526/4885 |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | MAPT 3514/4885ALDH1A1 2738/4885NPC1 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.